Myeloid Leukemia

More documents

Recommendations

Info

Index 301 materials, 257, 258, 260 principles, 254, 255 BsaXI restriction analysis, digestion, 260–262 gel electrophoresis, 260, 262 materials, 258 overview, 255, 257 polymerase chain reaction, 259, 260 PRV1 overexpression analysis with reverse transcriptionpolymerase chain reaction, amplification reactions, 269–271 cDNA verification, 269, 270 DNase treatment, 268 gel electrophoresis and analysis, 270, 271 materials, 266, 267 overview, 265, 266 peripheral blood granulocyte purification, 267, 270 reverse transcription, 269 RNA extraction, 267, 268 ET, see Essential thrombocythemia ETO, see AML1–ETO fusion F FIP1L1–PDGFRA fusion, deletion features, 177, 178 fluorescence in situ hybridization, materials, 179 probes, 185–187 white blood cell isolation and nucleic acid extraction, 179– 181, 186 polymerase chain reaction analysis, amplification reactions, 182–184, 186, 187 materials, 179 overview, 177 sequencing, 185, 187 white blood cell isolation and nucleic acid extraction, 179– 181, 186 reverse transcription-polymerase chain reaction, amplification reactions, 181, 182 cDNA synthesis, 181 gel electrophoresis and interpretation, 182 materials, 179 nested polymerase chain reaction, 181, 186 overview, 177 white blood cell isolation and nucleic acid extraction, 179– 181, 186 FISH, see Fluorescence in situ hybridization Flow cytometry, acute myeloid leukemia immunophenotyping, 242, 243 chimerism testing, 281, 282, 287 FLT3 mutations, detection, DNA extraction, 190, 191 DNA sequencing, 193, 194 Eco RV digestion, 192, 193 gel electrophoresis, 193 materials, 190 polymerase chain reaction, amplification reactions, 191, 192, 195, 196 primers, 191 functional effects, 189 types in acute myeloid leukemia, 189, 190, 194, 195 Fluorescence in situ hybridization (FISH), analysis, 21, 25 BCR-ABL fusion, interpretation and reporting, 111– 113 materials, 111, 112 minimal residual disease detection, 108, 111 probes, 108–110 prognostic value, 108, 109
302 Index chimerism analysis in sex-matched transplants, cell application to slides, 285 fluorescence microscopy, 287, 293 hybridization, 287, 288, 293 pretreatment, 287 washing and counterstaining, 287, 293 FIP1L1–PDGFRA fusion analysis, materials, 179 probes, 185–187 white blood cell isolation and nucleic acid extraction, 179– 181, 186 hybridization and washing, 20, 21, 24, 25 materials, 17, 18, 21, 22 principles, 15 G-banding, analysis, 20, 24 materials, 16, 17, 21 principles, 14, 15 slide preparation, 19, 20, 24 Giemsa banding, see G-banding Glivec, see Imatinib mesylate H Hierarchical clustering, DNA microarray analysis, 230–232 Hypereosinophilic syndrome, see FIP1L1–PDGFRA fusion I Idiopathic myelofibrosis (IMF), acute myeloid leukemia transformation, 254 clinical features, 253, 254 JAK2 V617F mutation detection, allele-specific polymerase chain reaction, amplification reactions, 258– 261 materials, 257, 258, 260 principles, 254, 255 BsaXI restriction analysis, digestion, 260–262 gel electrophoresis, 260, 262 materials, 258 overview, 255, 257 polymerase chain reaction, 259, 260 Imatinib mesylate (Glivec), BCR–ABL fusion mutation and resistance, detection of mutations, materials, 96, 97 semi-nested polymerase chain reaction, 95–102 sequencing reaction and analysis, 99, 100, 102–104 overview, 94, 95 chronic myeloid leukemia management, 70, 94 mechanism of action, 94 IMF, see Idiopathic myelofibrosis Immunophenotyping, see Acute myeloid leukemia J-L JAK2 V617F mutation, see Essential thrombocythemia; Idiopathic myelofibrosis; Polycythemia vera Karyotype, 9, 12, 111, 112 Leave-one-out cross-validation (LOOCV), DNA microarray analysis, 229 Locked nucleic acid, fragment detection in real-time quantitative polymerase chain reaction, 38, 39 LOOCV, see Leave-one-out crossvalidation M MDS, see Myelodysplastic syndrome Minimal residual disease (MRD),
Page 1 and 2:
M E T H O D S I N M O L E C U L A R
Page 3 and 4:
M E T H O D S I N M O L E C U L A R
Page 5 and 6:
© 2006 Humana Press Inc. 999 River
Page 7 and 8:
vi Preface comprehensive review of
Page 9 and 10:
viii Contents 11 Detection of the F
Page 11 and 12:
x Contributors D. GARY GILLILAND
Page 14 and 15:
RNA and DNA From Leukocytes 1 1 Iso
Page 16 and 17:
RNA and DNA From Leukocytes 3 mine
Page 18 and 19:
RNA and DNA From Leukocytes 5 late
Page 20 and 21:
RNA and DNA From Leukocytes 7 9. Us
Page 22 and 23:
RNA and DNA From Leukocytes 9 16. C
Page 24 and 25:
RNA and DNA From Leukocytes 11 3. I
Page 26 and 27:
Cytogenetic and FISH Techniques 13
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Real-Time RT-PCR Strategies 27 3 Ov
Page 42 and 43:
Real-Time RT-PCR Strategies 29
Page 44 and 45:
Real-Time RT-PCR Strategies 31 cifi
Page 46 and 47:
Real-Time RT-PCR Strategies 33 2.1.
Page 48 and 49:
Real-Time RT-PCR Strategies 35 Fig.
Page 50 and 51:
Real-Time RT-PCR Strategies 37 2.1.
Page 52 and 53:
Real-Time RT-PCR Strategies 39 the
Page 54 and 55:
Page 56 and 57:
Real-Time RT-PCR Strategies 43 duri
Page 58 and 59:
MyiQ single color 400 nm 585 nm 96
Page 60 and 61:
Real-Time RT-PCR Strategies 47 side
Page 62 and 63:
Table 2 Real-Time Quantitative Poly
Page 64 and 65:
Real-Time RT-PCR Strategies 51 AML-
Page 66 and 67:
Real-Time RT-PCR Strategies 53 the
Page 68 and 69:
Real-Time RT-PCR Strategies 55 plas
Page 70 and 71:
Real-Time RT-PCR Strategies 57 betw
Page 72 and 73:
Real-Time RT-PCR Strategies 59 Ct C
Page 74 and 75:
Page 76 and 77:
Real-Time RT-PCR Strategies 63 asse
Page 78 and 79:
Real-Time RT-PCR Strategies 65 21.
Page 80 and 81:
Real-Time RT-PCR Strategies 67 50.
Page 82 and 83:
Quantitative PCR for Monitoring CML
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Detection of BCR-ABL Mutations 93 5
Page 108 and 109:
Detection of BCR-ABL Mutations 95 F
Page 110 and 111:
Detection of BCR-ABL Mutations 97 2
Page 112 and 113:
Detection of BCR-ABL Mutations 99 o
Page 114 and 115:
Detection of BCR-ABL Mutations 101
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Deletion of Derivative Chromosome 9
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Diagnosis of PML-RARA-Positive APL
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Duplexed QZyme RT-PCR for APL Analy
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Diagnosis of AML1-MTG8 (ETO)-Positi
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Diagnosis of CBFB-MYH11-Positive AM
Page 178 and 179:
165 Table 1 Primers for CBFB-MYH11
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
FIP1L1-PDGFRA in Hypereosinophilic
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
FLT3 Mutations in AML 189 12 FLT3 M
Page 204 and 205:
FLT3 Mutations in AML 191 3.1.1. DN
Page 206 and 207:
FLT3 Mutations in AML 193 Table 2 R
Page 208 and 209:
FLT3 Mutations in AML 195 Fig. 2. D
Page 210 and 211:
FLT3 Mutations in AML 197 10. Kiyoi
Page 212 and 213:
WT1 Expression in AML and MDS 199 1
Page 214 and 215:
WT1 Expression in AML and MDS 201 T
Page 216 and 217:
Page 218 and 219:
WT1 Expression in AML and MDS 205 T
Page 220 and 221:
WT1 Expression in AML and MDS 207 F
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Classification of AML by DNA-Oligon
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
233 Classification of AML by DNA-Ol
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Classification of AML by Monoclonal
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
247 Classification of AML by Monocl
Page 262 and 263:
Page 264 and 265: Classification of AML by Monoclonal
Page 266 and 267: Detecting JAK2 V617F Mutation in MP
Page 278 and 279: PRV-1 Overexpression in PV and ET 2
Page 288 and 289: Chimerism Analysis 275 18 Chimerism
Page 290 and 291: Chimerism Analysis 277 1.2. Detecti
Page 292 and 293: Chimerism Analysis 279 3. Extractio
Page 294 and 295: Chimerism Analysis 281 14. 310 Gene
Page 296 and 297: Chimerism Analysis 283 12. Upon com
Page 298 and 299: Chimerism Analysis 285 Fig. 2. Calc
Page 300 and 301: Chimerism Analysis 287 4. Allow the
Page 302 and 303: Chimerism Analysis 289 capillary el
Page 304 and 305: Chimerism Analysis 291 and recipien
Page 306 and 307: Chimerism Analysis 293 Table 2 Comm
Page 308: Chimerism Analysis 295 12. Maas, F.
Page 311 and 312: 298 Index management, 128 AML, see
Page 313: 300 Index and AML, 213, 236, 238, 2
Page 317 and 318: 304 Index minimal residual disease
Page 319: 306 Index Stem cell transplantation
show all

Myeloid Leukemia

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?